NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS

Core Viewpoint - NervGen Pharma Corp. has filed a registration statement with the SEC to enhance its strategic initiatives and growth strategy in developing neuroreparative therapeutics for spinal cord injury and other neurological disorders [1][2]. Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on creating innovative therapies that enable the nervous system to repair itself in cases of neurotrauma and neurological diseases [4]. - The company is currently evaluating its lead candidate, NVG-291, in a Phase 1b/2a clinical study called CONNECT SCI for spinal cord injury [4]. Registration Statement Details - The registration statement filed with the SEC is not yet effective, meaning no securities can be sold or offers accepted until it becomes effective [2]. - The registration statement contains detailed information about the company and is available on EDGAR and from the company directly [3].